http://journalajorrin.com/index.php/AJORRIN/issue/feed Asian Journal of Research and Reports in Neurology 2019-11-14T10:56:21+00:00 Asian Journal of Research and Reports in Neurology contact@journalajorrin.com Open Journal Systems <p style="text-align: justify;"><strong>Asian Journal of Research and Reports in Neurology</strong>&nbsp;aims&nbsp;to publish&nbsp;high-quality&nbsp;papers (<a href="/index.php/AJORRIN/general-guideline-for-authors">Click here for Types of paper</a>) in all aspects of&nbsp;‘Neurology’. This journal facilitates the research and wishes to publish papers as long as they are technically correct, scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled,&nbsp;OPEN&nbsp;peer-reviewed, open access INTERNATIONAL journal.</p> http://journalajorrin.com/index.php/AJORRIN/article/view/30099 Validity of the Filipino Version of the Michigan Neuropathy Screening Instrument as a Measure of Distal Symmetric Peripheral Neuropathy among Diabetic Patients in the Clinic 2019-09-19T09:51:11+00:00 Ma. Luisa Gwenn Pabellano-Tiongson gpabellano@gmail.com Glennis Fiona J. Javelosa Armand Delo A. Tan <p><strong>Aims:</strong> To determine the accuracy of the Filipino version of the Michigan Neuropathy Screening Instrument (MNSI) in detecting distal symmetric peripheral neuropathy (DSPN) among diabetic patients, by comparing it to electromyography-nerve conduction velocity (EMG-NCV) as a gold standard.</p> <p><strong>Study Design:</strong> Cross-sectional study.</p> <p><strong>Place and Duration of the Study:</strong> Out-patient Department, University of the East Ramon Magsaysay Memorial Medical Center Inc., Philippines; From May 2016 to March 2017.</p> <p><strong>Methodology:</strong> Researchers tested 103 patients with Type 2 diabetes mellitus in the out-patient clinic of a single-centre tertiary hospital and determined the sensitivity and specificity of the Filipino version of the MNSI in identifying DSPN by comparing it to the EMG-NCV as a gold standard. Risk factors for neuropathy were also identified.</p> <p><strong>Results:</strong> The sensitivity of the combined Filipino MNSI questionnaire and clinical examination tool was 74.7%, and a specificity of 25%.&nbsp; The MNSI questionnaire scores had a statistically significant correlation to the degree of neuropathy as measured by the EMG-NCV (<em>P</em>= .01). There was no statistically significant difference between those with and without DSPN in terms of BMI, history of smoking, duration of diabetes, level of glycaemic control or presence of hypertension.</p> <p><strong>Conclusion:</strong> The Filipino MNSI may be used as a screening tool for distal symmetric peripheral neuropathy among diabetic patients due to its high sensitivity (74.7%). A positive Filipino MNSI will signal the need for further investigation using the EMG-NCV. The MNSI can be performed easily by a healthcare worker in the clinic to screen diabetic patients for neuropathy, and to monitor disease severity, preventing its complications.</p> 2019-09-19T00:00:00+00:00 ##submission.copyrightStatement## http://journalajorrin.com/index.php/AJORRIN/article/view/30100 Using Calcitonin Gene-related Peptide Monoclonal Antibodies for Migraine Headache Treatment and Prevention 2019-11-14T10:56:21+00:00 Nour Al-Kharrat Gunay Arsoy gunay118@hotmail.com <p>Novel drugs are available now for treating and preventing migraine attacks. Those new drugs have a special strategy to treat migraine by modifying the signaling of calcitonin gene- related peptide (CGRP) which is a strong neuropeptide released from the nerves. Monoclonal antibodies (mAbs) have been developed for targeting the CGRP pathway by binding the CGRP ligand (eptinezumab, galcanezumab fremanezumab,) or the CGRP receptor (erenumab). Recent studies show that mAbs have several advantages over small molecule antagonists, including high selectivity and reduced potential for drug–drug interactions. In this article we reviewed literature to assess whether mABs can be used for treatment of acute and chronic migraine safely compared to classical antimigraine agents.</p> 2019-11-14T00:00:00+00:00 ##submission.copyrightStatement##